Mydecine Innovations Group Inc - Total Voting Rights
30 Abril 2024 - 11:29AM
UK Regulatory
Mydecine Innovations Group Inc - Total
Voting Rights
PR Newswire
LONDON, United Kingdom, April 30
MYDECINE
INNOVATIONS GROUP INC.
(the
"Company" or "Mydecine")
TOTAL
VOTING RIGHTS
VANCOUVER, BC - (30 April
2024) In accordance with the FCA's Disclosure Guidance and
Transparency Rules, as at 30 April
2024, the Company's issued share capital consists of
61,755,385 Ordinary
Shares of no par value, each with one voting right. The Company
does not hold any Ordinary Shares in treasury. Therefore, the total
number of voting rights in the Company is
61,755,385.
The above
figure of
61,755,385 should be
used by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
For
more information, please contact:
Media
Contact
pr@mydecineinc.com
investorrelations@mydecineinc.com
On
behalf
of
the
Board
of
Directors
Joshua
Bartch,
Chief
Executive
Officer
contact@mydecineinc.com
AQSE
Corporate Advisor
Novum
Securities Limited
David Coffman/ George
Duxberry
Tel: +44
(0)207 399 9400
For
further
information
about
Mydecine,
please
visit
the
Company's
profile
on
SEDAR
at https://sedar.com/
or
visit the
Company's website at
https://www.mydecine.com/.
About
Mydecine
Innovations
Group
Inc.
Mydecine
Innovations Group™ is a biotechnology company developing the next
generation of innovative medications and therapies to address
mental health disorders such as nicotine addiction and
post-traumatic stress disorder (PTSD). The core strategy blends
advanced technology with an elaborate infrastructure for drug
discovery and development. Mydecine's dedicated multinational team
constantly develops new paths for breakthrough treatment solutions
in areas with considerable unmet needs. By collaborating with some
of the world's leading specialists, the Company aspires to
responsibly speed up the development
of
breakthrough
medications
to
provide
patients with
safer
and
more
effective
treatment
solutions.
At the
same
time,
Mydecine's
approach
focuses
on
the
next
generation
of
psychedelic
medicine
by
creating
innovative compounds with unmatched therapeutic potential through
its clinical trial efforts with world-class scientific and
regulatory
expertise.
Learn
more
at:
https://www.mydecine.com/ and
follow
the
Company
on
Twitter,
LinkedIn,
YouTube,
and
Instagram.
Mydecine Innovations (AQSE:MYIG)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Mydecine Innovations (AQSE:MYIG)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
